Boehringer Ingelheim Pharmaceuticals, Inc.

Bio-mega/boehringer Ingelheim Research Inc.

Boehringer Ingelheim (Canada) Ltd.

Boehringer Ingelheim International Gmbh

University of Michigan

Boehringer Ingelheim Pharma Gmbh & Co Kg

Neil Moss

Abdelhakim Hammach

Daniel R Goldberg

Pierre Louis Beaulieu

Pier Francesco Cirillo

Donghong Amy Gao

John R Regan

Usha R Patel

Zhaoming Xiong

John Robert Proudfoot

Hidenori Takahashi

Mario G Cardozo

Victor Marc Kamhi

Montse Llinas-Brunet

Tina Marie Morwick

Roger John Snow

Rajashekhar Betageri

Anthony S Prokopowicz

Eugene R Hickey

Ming-Hong Hao

Derek Cogan

Lifen Wu

Christopher Ronald Sarko

Matthew Russell Netherton

Thomas A Gilmore

Daniel Kuzmich

Charles Lawrence Cywin

Julian Adams

Xiao-Jun Wang

Alan David Swinamer

Weimin Liu

James A Shayman

Scott D Larsen

Emily Elizabeth Freeman

Steffen Breitfelder

Sanxing Sun

Michael William Wilson

Robert Deziel

Christopher Pargellis

Jean-Marie Ferland

Matt Aaron Tschantz

Raymond Plante

Kevin Chungeng Qian

Mark Stephen Ralph

Craig Andrew Miller

Ronald A Aungst, Jr

Gregory Paul Roth

Paul S Riska

Robert D Selliah

Antonio Jose Del Moral Barbosa, Jr

Rene Marc Lemieux

Heather Tye

Mark Whittaker

Zhidong Chen

Qin Jiang

Pui Leng Loke

Jiang-Ping Wu

Alexander Heim-Riether

Steven Richard Brunette

Pingrong Liu

Fariba Soleymanzadeh

Bryan Patrick McKibben

Jean A Gauthier

John DiMaio

Joerg Bentzien

Ji Wang

Robert D&eacute;ziel

Jennifer A Kowalski

Rajiv Sharma

Joshua Courtney Horan

Nicholas James Mayhew

Hui Yu

Rajashehar Betageri

Kim Hutchings

Philip Dean Ramsden

Antonio J Barbosa

Thomas M Kirrane

Yang Yu

Michael David Lawlor

Robert D Eziel

Andre White

Pier Francesco

Kristen Mueller

Monica H Moriak

Pierre Lavalle/ E

Zohreh Sajjadi Hashemi

Louis Grenier

Robert De/ Ziel

Montse Llinas Brunet

Samantha Jayne Bamford

Joerg Martin Bentzien

Bryan Mckibben

Donghong A Gao

Antonio Jose Del Moral Barbosa

Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.

Glucosylceramide synthase inhibitors and therapeutic methods using the same

Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds. 

Serotonin 5-HT2B receptor inhibitors

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

The application relates to compounds of formula Ia and analogues thereof wherein Rto Rand X are as defined herein. The invention also relates to the use of the compounds of formula Ia as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.

Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors

Disclosed are amide compounds of formula (I): wherein Ar, Q, Y and R-Rof formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases

Disclosed are compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Cytokine inhibitors

Disclosed are compounds of formula (I) Where Ar, X, Y, Q, W, R, R, R, Rand Rare defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. The compounds are also useful for treating diseases or conditions related to oncology and anticoagulant or fibrinolytic therapy. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Disclosed are compounds of formula(I): wherein R, R, W and X of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Fluorinated di-aryl urea compounds

Disclosed are methods of treating acute and chronic inflammation in the lung caused by inhalation of smoke, endometriosis, Behcet's disease, uveitis, ankylosing spondylitis, pancreatitis, cancer, Lyme disease, sepsis, chronic obstructive pulmonary disease, traumatic arthritis, congestive heart failure and restenosis following percutaneous transluminal coronary angioplasty, known to be cytokine mediated, using aromatic heterocyclic compounds described in WO 00/55139.

Methods of treating cytokine mediated diseases

Disclosed are benzimidazolone compounds of formulas (I) & (II): wherein R, R, R, R, R, X, L, m, n and t are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds 

Heterocyclic compounds

Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar,Ar,L,Q and X are described herein.

Disclosed are compounds of formula (I):wherein R, R, W and X of formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Disclosed are compounds useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Compounds useful as anti-inflammatory agents

Disclosed are novel compounds of formula (I):wherein Ar, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.

Heterocyclic compounds useful as inhibitors of tyrosine kinases

Growing community of inventors

Ridgefield, CT, United States of America

Neil Moss